Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.74 |
| ▸ | DAO | P14920 | 4/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | BRS3 | P32247 | 3/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20204667 | 0.88 | CAPN1 (0.58) | CAPN1DAOESR1ESR2MAPT | |
| SCHEMBL21333942 | 0.85 | CAPN1 (1.00) | CAPN1DAOKDM4AAOC3BRS3 | |
| SCHEMBL21707855 | 0.84 | CAPN1 (0.53) | CAPN1DAOESR1ESR2MAPT | |
| SCHEMBL20204670 | 0.81 | CAPN1 (0.49) | CAPN1ESR1ESR2GPR84 | |
| SCHEMBL20204597 | 0.74 | CAPN1 (0.55) | CAPN1DAOKDM4AAOC3BRS3 | |
| SCHEMBL21707883 | 0.73 | CAPN1 (0.77) | CAPN1DAOKDM4AAOC3BRS3 | |
| SCHEMBL21393119 | 0.71 | CAPN1 (0.49) | CAPN1DAO | |
| SCHEMBL10567513 | 0.70 | ESR1 (0.45) | CAPN1ESR1ESR2AOC3BRS3 | |
| SCHEMBL12598583 | 0.70 | AOC3 (0.69) | ESR1ESR2AOC3ALDH1A1 | |
| SCHEMBL21707863 | 0.69 | CAPN1 (0.71) | CAPN1DAOKDM4AAOC3BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115651069-A | Cyclochromo-threo-casein-valine-phenylpropanoid with hepatoma cytotoxicity and alpha-glucosidase inhibition activity and preparation method thereof | 安徽农业大学 | 2023-01-31 | — | — | CN | claimed |
| WO-2025083273-A1 | BINDING MOLECULES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-04-24 | — | — | WO | disclosed |
| EP-4490205-A2 | USES AND METHODS FOR IL-2, IL-13, AND IL-4 CYTOKINE BIFUNCTIONAL MOLECULES | Medicenna Therapeutics, Inc. (CA) | 2025-01-15 | — | — | EP | disclosed |
| EP-4444751-A1 | IMMUNOTHERAPY FOR CANCER | Cancer Research Technology Limited (GB) | 2024-10-16 | — | — | EP | disclosed |
| CN-115716865-B | Cyclic color-threo-tyr-valyl-leupeptin with hepatoma cytotoxicity and alpha-glucosidase inhibition activity and preparation method thereof | 安徽农业大学 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023170475-A2 | USES AND METHODS FOR IL-2, IL-13, AND IL-4 CYTOKINE BIFUNCTIONAL MOLECULES | MEDICENNA THERAPEUTICS, INC. (CA) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023105248-A1 | IMMUNOTHERAPY FOR CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-06-15 | — | — | WO | disclosed |
| EP-4172198-A1 | TAU BINDING MOLECULES | Gen2 Neuroscience Limited (GB) | 2023-05-03 | — | — | EP | disclosed |
| CN-115716865-A | Cyclochro-threo-casein-valine-leucine peptide with hepatoma cytotoxicity and alpha-glucosidase inhibition activity and preparation method thereof | 安徽农业大学 | 2023-02-28 | — | — | CN | disclosed |
| CN-115651069-A | Cyclochromo-threo-casein-valine-phenylpropanoid with hepatoma cytotoxicity and alpha-glucosidase inhibition activity and preparation method thereof | 安徽农业大学 | 2023-01-31 | — | — | CN | disclosed |
| US-11548916-B2 | Anti-infective compound | EBERHARD KARLS UNIVERSITAET TUEBINGEN (DE) | 2023-01-10 | — | — | US | disclosed |
| EP-3990487-A1 | TAU EPITOPE AND BINDING MOLECULES | Gen2 Neuroscience Limited (GB) | 2022-05-04 | — | — | EP | disclosed |
| CN-114262690-A | Clonal strains of attenuated vaccinia virus and methods of use thereof | 吉恩勒克斯公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11124498-B2 | Compositions and methods for modulating protease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124498-B2 | Compositions and methods for modulating protease activity | RNASE1, ADAM8, CTRL | CAPN1 81/4885DAO 2868/4885ESR1 1853/4885 |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | RNASE1, ADAM8, CTRL | CAPN1 81/4885DAO 2868/4885ESR1 1853/4885 |
| US-11548916-B2 | Anti-infective compound | LCT, VIP, TLR5 | CAPN1 3526/4885DAO 805/4885ESR1 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.